IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

50.27 51.33 41.01 36.74
P/S ratio
12.28 12.64 10.07 9.13
P/FCF ratio
59.28 56.88 42.30 33.60
P/Operating CF
127.19 152.94 168.09 119.73
P/B ratio
32.78 33.89 28.76 25.78
EV/Sales
12.36 12.71 10.12 9.18
EV/EBITDA
35.60 36.33 28.94 25.93
EV/FCF
59.65 57.16 42.53 33.80
Current Ratio
1.18 1.23 1.12 1.17
Net Debt/EBITDA
0.81 0.76 0.62 0.54
Debt/Equity
0.34 0.28 0.29 0.28
Earnings Yield
1.99% 1.95% 2.44% 2.72%
Free Cash Flow Yield
1.69% 1.76% 2.36% 2.98%
Free Cash Flow per Share
4.47 4.05 2.92 4.06
Book value per Share
19.49 19.96 19.54 20.42
Free Cash Flow
357.88 326.13 232.46 320.62
EV/EBIT
39.42 40.21 32.01 28.67
Other line items

Show all line items

Columns are period end dates